1. Selected Highlights of the Latest Advances in PAH

2. Management of PAH

3. Program Overview

4. Risk Assessment in PAH: Learnings From the French Registry

5. Achievement of Low-Risk Criteria

6. Low-Risk Criteria at Diagnosis and at First Re-Evaluation

7. Baseline Criteria: 1017 Patients

8. Low-Risk Criteria Achieved → 3 Year *Survival

9. French Registry: BNP Subset Analysis

10. Comprehensive Risk Stratification at Early Follow-Up Determines Prognosis

11. Risk Stratification: COMPERA Registry

12. Conclusion

13. Newly Released Trial Data:

14. Selected Trials

15. PATENT-1 Study

16. PATENT Subgroup Analysis (Treatment-Naive and Pretreated)

17. MOTION Trial Design

18. MOTION Trial Baseline Characteristics

19. MOTION Results

20. EXPERT Trial

21. EXPERT Summary and Conclusions

22. Conclusions

23. Full Results of the RESPITE Trial

24. Management of PAH

25. Different Mechanisms of Action on the Nitric Oxide-Cyclic GMP Pathway

26. RESPITE

27. Patient Disposition and Flow in RESPITE

28. RESPITE: Safety Outcomes

29. Demonstrated Benefit

30. NT-proBNP Levels: Transition to Riociguat

31. Change in Hemodynamics From Baseline to Week 24

32. RESPITE Implications and Outlook

33. Concluding Comments

34. Points to Remember

35. Abbreviations

36. Abbreviations (cont)

37. Abbreviations (cont)